We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The phase 3 study will evaluate brepocitinib’s efficacy ...

Intellia Therapeutics details progress in Phase 3 trials for NTLA-2002 and nex-z, anticipating key regulatory submissions by 2026. Intellia Therapeutics has announced the initiation of the global ...

Felzartamab is still an investigational drug that has not yet received regulatory approval, which poses a risk for investors and stakeholders regarding its eventual market success. The need for a ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN) a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of ...

“The positive results of the Phase 3 VERIFY study across the primary and all key secondary endpoints provide compelling evidence of the potential for rusfertide as a first-in-class ...

The RELIEVE trial assesses remibrutinib's efficacy and safety in generalized myasthenia gravis, involving 180 participants in a 6-month double-blind study. Remibrutinib has shown a positive safety ...

A phase II open-label study of olutasidenib post-transplant maintenance therapy for patients with IDH1-mutated myeloid malignancies. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...

A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last week is offset by a challenging tolerability profile. Analysts got an ...

SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (GOSS) (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the ...

Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...